Cures Within Reach: Impacting Blood Cancers through Clinical Repurposing Trials
Research Admin Offices:
- HRS
Funding Type:
GrantOpportunity Type:
- Grant
Value:
Up to $60,000 US, plus an institutional match of 20%.
Disciplines:
- Health Sciences
Sponsors:
Deadlines:
Internal Deadline:
July 15, 2024Sponsor Deadline:
July 29, 2024Additional Dates:
- LOI HRS Due Date - July 15, 2024
- LOI Sponsor Due Date - July 29, 2024
Description:
This opportunity supports clinical repurposing trials to address unsolved blood cancers, with a preference for trials impacting multiple myeloma and/or myelodysplastic syndromes. Of specific interest is generic or proprietary approved therapies that could be repurposed to create “new” treatments to 1) reduce the symptoms, progression or incidence of; 2) restore function lost to; or 3) reduce or eliminate severe side effects of currently used therapies for any blood cancer, thereby improving patient outcomes and quality of life.
Resources:
Contact:
If applying from the Faculty of Health Sciences, unless otherwise indicated, you no longer need to send documents to HRS Intake. Your first point of contact is your assigned Senior Grants Advisor.